New enhanced and effective method for staging cancer to detect lymph nodes after fat-dissociation

Fujino,Shiki; Miyoshi,Norikatsu; Ohue,Masayuki; Noura,Shingo; Tomita,Yasuhiko; Yano,Masahiko; Sakon,Masato

doi:10.3892/or.2014.3315

New enhanced and effective method for staging cancer to detect lymph nodes after fat-dissociation

Authors:
- Shiki Fujino
- Norikatsu Miyoshi
- Masayuki Ohue
- Shingo Noura
- Yasuhiko Tomita
- Masahiko Yano
- Masato Sakon
View Affiliations

Affiliations: Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka 537-8511, Japan, Department of Pathology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka 537-8511, Japan
Published online on: July 9, 2014 https://doi.org/10.3892/or.2014.3315
Pages: 922-926

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pathologic staging is a key factor in the treatment and outcome of cancer patients, and lymph node status plays a pivotal role in this staging process. Several methods of lymph node assessment, such as the fat clearance, Schwartz solution and GEWF solution, are unpopular as they require a significant amount of time (1‑9 days) to clear the fat of the resected mesentery and to visualize the lymph nodes. In the present study, we discussed a more simple and effective method, called the fat‑dissociation method, which clears the fat using enzymes and allows for easy identification of lymph nodes around vessels. This new procedure facilitates precise staging of cancer which directs the post-operative treatment plan.

View Figures

View References

1	Thun MJ, DeLancey JO, Center MM, Jemal A and Ward EM: The global burden of cancer: priorities for prevention. Carcinogenesis. 31:100–110. 2010. View Article : Google Scholar : PubMed/NCBI
2	Center for Cancer Control and Information Services NCC. Japan recent cancer statistics. 2011, http://ganjoho.jp/public/statistics/pub/statistics01.html. Accessed December 30, 2013
3	Van Cutsem E, Nordlinger B and Cervantes A; ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol. 21(Suppl 5): v93–v97. 2010.
4	Labianca R, Nordlinger B, Beretta GD, et al: Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24(Suppl 6): vi64–vi72. 2013. View Article : Google Scholar : PubMed/NCBI
5	Network NCC NCCN guidlines for treatment of cancer by site: Colon/Rectal Cancer. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed December 30, 2013
6	Hida J, Mori N, Kubo R, et al: Metastases from carcinoma of the colon and rectum detected in small lymph nodes by the clearing method. J Am Coll Surg. 178:223–228. 1994.PubMed/NCBI
7	Morikawa E, Yasutomi M, Shindou K, et al: Distribution of metastatic lymph nodes in colorectal cancer by the modified clearing method. Dis Colon Rectum. 37:219–223. 1994. View Article : Google Scholar : PubMed/NCBI
8	Chapman B, Paquette C, Tooke C, et al: Impact of Schwartz enhanced visualization solution on staging colorectal cancer and clinicopathological features associated with lymph node count. Dis Colon Rectum. 56:1028–1035. 2013. View Article : Google Scholar
9	Gregurek SF and Wu HH: Can GEWF solution improve the retrieval of lymph nodes from colorectal cancer resections? Arch Pathol Lab Med. 133:83–86. 2009.PubMed/NCBI
10	Newell KJ, Sawka BW, Rudrick BF and Driman DK: GEWF solution. Arch Pathol Lab Med. 125:642–645. 2001.PubMed/NCBI
11	ESMO Oncology Clinical Practice Guidlines. http://www.esmo.org/Guidelines-Practice/Clinical-Practice-Guidelines. Accessed December 30, 2013
12	Japanese Society for Cancer of the Colon and Rectum. JSCCR Guidelines 2010 for the Treatment of Colorectal Cancer; Kanehara, Tokyo. pp. 13–15. 2010
13	Japanese Society for Cancer of the Colon and Rectum. Japanese Classification of Colorectal Carcinoma. 8th edition. Kanehara, Tokyo: pp. 11–14. 2013
14	Miyoshi N, Ishii H, Nagai K, et al: Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci USA. 107:40–45. 2010. View Article : Google Scholar : PubMed/NCBI
15	Miyoshi N, Ishii H, Nagano H, et al: Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell. 8:633–638. 2011. View Article : Google Scholar : PubMed/NCBI
16	Figueredo A, Charette ML, Maroun J, Brouwers MC and Zuraw L: Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol. 22:3395–3407. 2004.
17	Gill S, Loprinzi CL, Sargent DJ, et al: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 22:1797–1806. 2004. View Article : Google Scholar : PubMed/NCBI
18	Benson AB III, Schrag D, Somerfield MR, et al: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 22:3408–3419. 2004. View Article : Google Scholar : PubMed/NCBI
19	André T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New Engl J Med. 350:2343–2351. 2004.
20	André T, Boni C, Navarro M, et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 27:3109–3116. 2009.PubMed/NCBI
21	Kuebler JP, Wieand HS, O’Connell MJ, et al: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 25:2198–2204. 2007. View Article : Google Scholar